Orphan Drugs in Oncology-Reference-Cited by-同舟云学术

Orphan Drugs in Oncology

Published:2018-12-13 Issue: Volume: Page:109-142
ISSN:0080-0015
Container-title:Regulatory and Economic Aspects in Oncology
language:
Short-container-title:

Author:

Korchagina Daria,Jaroslawski Szymon,Jadot Guy,Toumi Mondher

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-030-01207-6_8

Reference91 articles.

1. Assmann G, Schmidt U, Drechsler M, Pfannkuche M (2014) Conditional resolutions in the among early benefit assessment. Value Health 17. Available: https://www.ispor.org/research_pdfs/48/pdffiles/PHP225.pdf . Accessed 23 Jan 2017

2. Augustine EF, Adams HR, Mink JW (2013) Clinical trials in rare disease: challenges and opportunities. J Child Neurol 28:1142–1150

3. BioSeeker Group (2016) Orphan drugs in oncology drug pipeline update

4. Bouslouk M (2016) G-BA benefit assessment of new orphan drugs in Germany: the first five years. Expert Opin Orphan Drugs 4:453–455

5. Brockis E, Marsden G, Cole A, Devlin N (2016) A review of NICE methods across health technology assessment programmes: differences, justifications and implications. Office of Health Economics

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures;Cancers;2024-04-12

2. Trends in orphan medicinal products approvals in the European Union between 2010–2022;Orphanet Journal of Rare Diseases;2024-02-27

3. Review time of oncology drugs and its underlying factors: an exploration in China;Frontiers in Pharmacology;2023-11-01

4. Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of registered clinical trials;Critical Reviews in Oncology/Hematology;2023-01

5. A systematic review of moral reasons on orphan drug reimbursement;Orphanet Journal of Rare Diseases;2021-06-30